Jubilant gets USFDA nod for Drax Exametazime

Updated: Mon, Aug 21, 2017
05:14 pm
PTI
RELATED NEWS
US lawmakers reintroduce legislation enforcing fair trade with China US lawmakers reintroduce legislation enforcing fair trade with China
Gold steady on global growth, Sino-U.S. trade worries Gold steady on global growth, Sino-U.S. trade worries
Global Markets: Asian shares dip, worries over growth and trade sour mood Global Markets: Asian shares dip, worries over growth and trade sour mood

Drug firm Jubilant Life Sciences today said it has received new drug application approval from the US health regulator for Drax Exametazime.

Jubilant Pharma Ltd, a wholly-owned subsidiary of the company, through its Canada-based arm Jubilant Draximage Inc has received new drug application (NDA) approval from the United States Food and Drug Administration (USFDA) for Drax Exametazime, Jubilant Life Sciences said.

"This approved NDA is indicated for leukocyte (white blood cell) labelled scintigraphy as an adjunct in the localisation of intra-abdominal infection and inflammatory bowel disease," it said in a BSE filing.

This is the sixth approval the company has received from the USFDA during the current financial year, it added.

Shares of Jubilant Life Sciences closed 1.33 per cent down at Rs 695 on BSE.

 

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)